GUSHENGTANG HOLDINGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.55 HKD | +0.40% |
|
-2.72% | -25.50% |
| Sales 2024 * | 3.05B 420M 3.28B | Sales 2025 * | 3.91B 537M 4.2B | Capitalization | 8.47B 1.17B 9.1B |
|---|---|---|---|---|---|
| Net income 2024 * | 355M 48.83M 381M | Net income 2025 * | 473M 65.06M 508M | EV / Sales 2024 * | 2.36 x |
| Net cash position 2024 * | 1.26B 173M 1.35B | Net cash position 2025 * | 1.55B 214M 1.67B | EV / Sales 2025 * | 1.77 x |
| P/E ratio 2024 * |
24.1
x | P/E ratio 2025 * |
18.2
x | Employees | 2,659 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.22% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.40% | ||
| 1 week | -2.72% | ||
| Current month | +0.13% | ||
| 1 month | -12.27% | ||
| 3 months | -14.76% | ||
| 6 months | -23.05% | ||
| Current year | -25.50% |
1 week
36.85
39.00
1 month
36.8544.10
Current year
34.9550.80
1 year
34.7552.40
3 years
14.8660.25
5 years
14.8660.25
10 years
14.8660.25
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Liang Tu
CEO | Chief Executive Officer | 45 | 09-12-31 |
Shi Gang Deng
DFI | Director of Finance/CFO | 51 | 19-08-04 |
Peng Yu
SEC | Corporate Secretary | 35 | 21-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jing Sheng Huang
BRD | Director/Board Member | 66 | 14-08-20 |
Xu Jin
BRD | Director/Board Member | 55 | 21-11-15 |
Jian Gao
BRD | Director/Board Member | 61 | 21-05-24 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 114 M€ | +7.08% | - | |
| 0.00% | 32 M€ | +4.54% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-03 | 37.55 | +0.40% | 291 600 |
| 24-07-02 | 37.4 | -0.27% | 674,384 |
| 24-06-28 | 37.5 | -1.32% | 1,043,968 |
| 24-06-27 | 38 | -1.55% | 1,292,000 |
| 24-06-26 | 38.6 | +1.31% | 900,200 |
Delayed Quote Hong Kong S.E., July 03, 2024 at 04:08 am EDT
More quotes
Gushengtang Holdings Ltd is a China-based company mainly engaged in traditional Chinese medicine (TCM) medical and health services. The Company operates in two segments. Medical and Health Solutions segment is engaged in providing customers with traditional Chinese medical and health services through offline medical institutions and online medical and health platforms, including consultation, diagnosis, prescription services, decoctions and physical therapy. Sales of Medical and Health Products segment is mainly responsible for the sales of related products. The Company's main products include Ejiao, Cordyceps, cubilose, dendrobium, American Ginseng and other medicinal materials. The Company also provides honey, Ejiao cake and other nutritional products.
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
34.8
CNY
Average target price
59.84
CNY
Spread / Average Target
+71.93%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -25.50% | 1.17B | |
| -63.24% | 61.47M |
- Stock Market
- Equities
- 2273 Stock
